6 results about "Prostate-specific antigen" patented technology

The invention discloses an electrochemical aptamer sensor, a preparation method and application thereof and a prostate specific antigen detection method, and successfully develops a reliable electrochemical biological aptamer sensor which is used for ultra-sensitive detection of PSA (Prostate Specific Antigen). The aptamer is used as a biological recognition element to specifically recognize PSA. Nanoporous gold (NP-Gold) having a high specific surface area and excellent conductivity is used as a support material. According to the present invention, the double-strand specific nuclease (DSN) is adopted to reduce the noise signal, and the provided aptamer sensor shows excellent performance when the PSA in the clinical serum sample is determined, and has characteristics of high sensitivity, strong anti-interference ability and reliable stability. Due to the unique advantages, the aptamer sensor becomes a very potential choice for detecting the PSA.

The invention discloses a rare earth nanoprobe, a preparation method and application thereof, and belongs to the technical field of biomedical detection.According to the technology, the rare earth nanoprobe with the high fluorescence quantum yield is synthesized, specific recognition of tumor markers is achieved through the aptamer technology, and the detection sensitivity and selectivity are remarkably improved. The fluorescence signal amplification effect of the rare earth nanoprobe and the modern fluorescence detection technology are innovatively combined, so that simultaneous detection of multiple tumor markers such as carcino-embryonic antigen (CEA), prostate specific antigen (PSA) and alpha fetoprotein (AFP) becomes possible. According to the method, the detection limit reaches the pg / mL level, the operation is simple and convenient, the cost is low, and the feasibility of clinical application is greatly improved. Besides, through multiple detection design, the detection efficiency and accuracy are further improved, an effective tool is provided for early diagnosis, curative effect monitoring and prognosis evaluation of tumors, and wide clinical application prospects and market potential are shown.

The application discloses an electrochemical aptamer sensor and a preparation method and application thereof, and a prostate specific antigen detection method, and successfully develops a reliable electrochemical biological aptamer sensor for super-sensitivity detection of PSA. An aptamer is used as a biological recognition element to specifically recognize PSA. Nano-porous gold (NP-Gold) with high specific surface area and excellent conductivity is used as a support material. With the help of double-stranded specific nuclease (DSN), noise signals are reduced, the proposed aptamer sensor shows excellent performance in determination of PSA in clinical serum samples, has high sensitivity, strong anti-interference ability and reliable stability. These unique advantages make the aptamer sensor a potential choice for detection of PSA.

The invention belongs to the field of biological medicine, and provides an active compound for treating prostatic cancer and a preparation method thereof. A-B-C-D-P five-module linear connection design is adopted, wherein the A module is a prostate specific membrane antigen targeting binding unit, the B module is a prostate specific antigen enzyme digestion recognition sequence HSSKLQ, the C module is a cathepsin B-responsive Val-Cit-p-aminobenzyl self-destruction unit, the D module is a reduction-responsive disulfide bond connecting arm, and the P is an anti-tumor pharmacodynamic fragment. A coupling reaction is accurately controlled through a continuous flow microchannel technology, controllable self-assembly of the 20-60-nanometer nano aggregate is achieved, the average hydration diameter dispersion coefficient is not larger than 0.20, and the nano aggregate stably exists in plasma and selectively releases drugs in a tumor microenvironment. Multiple contradictions among prodrug system process manufacturability, intracellular response release and stable dispersion of the preparation are solved, and wide clinical application value is achieved.

The present invention relates to a biomarker composition for diagnosing and predicting prognosis of prostate cancer, and that the detection rate and expression level of gene combination composed with AR (Androgen receptor), AR-V7 (Androgen receptor variant 7), EpCAM (Epithelial cell adhesion molecule) in blood tumor cells (CTC) isolated from patients, Epithelial cell adhesion molecule), KRT-19 (Cytokeratin 19), PSA (Prostate specific antigen), and PSMA (Prostate specific membrane antigen) in circulating tumor cells (CTCs) isolated from patients is related to the level of malignancy in prostate cancer is confirmed and thus the gene combination provides as a biomarker for prostate cancer diagnosis and a biomarker for prognosis prediction of prostate cancer.

The invention discloses a separated antibody or antigen binding fragment specifically bound with PSA, the antibody has high detection sensitivity to PSA, the affinity can reach 2.9 * 10 <-9 > M, and a variable region sequence of the antibody is further obtained through sequencing. The antibody can be used for preparing a detection reagent of a prostate specific antigen, is further used for detecting and diagnosing prostate cancer, and has a good application prospect.